Roth Capital maintained a Buy rating on Cytokinetics (NASDAQ: CYTK), and raised the price target to $22.00 (from $18.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Amgen (AMGN) Announces ABP 501 Phase 3 Met Primary Endpoint in RA vs AdalimumabNovember 9, 2015 5:31 PM Amgen (AMGN), Cytokinetics (CYTK) Announce COSMIC-HF Met Primary EndpointNovember 9, 2015 6:16 AM Amgen and Cytokinetics Announce Late-Breaking Presentation of COSMIC-HF Trial at AHA Scientific Sessions 2015November 8, 2015 3:45 PM Amgen And Cytokinetics Announce Late-Breaking Presentation Of COSMIC-HF Trial At AHA Scientific Sessions 2015November 8, 2015 3:45 PM Amgen Presents Detailed Data Comparing Etelcalcetide With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving HemodialysisNovember 7, 2015 3:00 PM Amgen's (AMGN) NDA for Etelcalcetide Accepted by FDANovember 6, 2015 4:02 PM FDA Accepts Amgen's New Drug Application For Novel Intravenous Calcimimetic EtelcalcetideNovember 6, 2015 4:01 PM Cytokinetics Announces Results From COSMIC-HF to be Presented in Late Breaking Clinical Trial Session at American Heart Association Scientific SessionsNovember 6, 2015 7:30 AM After big spending and hard lobbying, Pfizer eyes new tax homeNovember 6, 2015 1:17 AM Amgen To Present At The Credit Suisse 24th Annual Healthcare ConferenceNovember 5, 2015 4:01 PM Key Data For Amgen Medicines In Relapsed Multiple Myeloma And Acute Lymphoblastic Leukemia To Be Presented At ASH 2015November 5, 2015 9:15 AM